AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...
AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
Imfinzi (durvalumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment ...